Good afternoon, welcome to The Oncology Institute's Q4 and year-end 2022 earnings conference call. Today's call is being recorded, we have allocated one hour for prepared remarks and Q&A. At this time, I'd like to turn the conference over to Mark Hueppelsheuser, General Counsel at TOI. Thank you. You may begin. The press release announcing The Oncology Institute's results for the Q4 and year- end 2022 are available at the investor section of the company's website, theoncologyinstitute.com. A replay of this call will also be available at the company's website after the conclusion of this call. Before we get started, I would like to remind you of the company's safe harbor language. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. For a further discussion of risks related to our business, see our filings with the SEC. This call will also discuss non-GAAP financial measures such as adjusted EBITDA. Reconciliation of these non-GAAP measures to the most comparable GAAP measures are included in the earnings release furnished to the SEC and available on our website. Joining me on the call today is our CEO, Brad Hively, and our CFO, Mihir Shah. Following our prepared remarks, we'll open the call for your questions. With that, I'll turn the call over to Brad. Thanks, Mark, and thank you to everyone joining us today. I'll start with a review of our 2022 performance, and then Mihir will provide more detail around our 2022 financial results. We'll then touch on 2023. 2022 was our first full year as a public company. I'm pleased with the progress we made driving our growth strategy with contributions from both organic and acquired growth. Despite facing certain headwinds during the year, including Medi-Cal preventing us from dispensing oral prescriptions to a portion of our California patients, a tight labor market, and delays in acquired revenue, we surpassed the top end of our revised 2022 guidance for revenue, gross profit, and adjusted EBITDA, and achieved our revised guidance for covered lives. We also achieved our original guidance for gross profit, adjusted EBITDA, and covered lives. We ended the year strong, achieving record revenue in the Q2, adding two new clinics, including the acqui-hire of a clinic in Chino, California, and a de novo opening in South Florida. This growth expands TOI's network of 101 specialty-trained physicians and advanced practice providers to 62 clinics across five states. Annually, this growth represents a 17% increase in the number of clinics and providers. As mentioned on our Q3 call, we recently opened our fifteenth market with our expansion into South Florida through the acquisition of two practices, Broward Oncology Associates and Hematology/Oncology Associates of Miami. We also announced a new de novo clinic in Plantation, Florida, which opened in December. We are pleased to announce the addition of ChenMed to our gain share partners in Florida. Our partnership with these groups helps to advance our goal of bringing value-based oncology care to Florida. I'll now provide some additional highlights from 2022. We completed a $110 million strategic investment from Deerfield Management Company through secured senior convertible notes on August 9, 2022. We ended 2022 with $132 million in cash equivalents and investments. We increased our market count to 15 at year-end from 10 the prior year, including new markets in California, Florida, and Texas. We remediated two of the previously disclosed material weaknesses surrounding controls over review of revenue and segregation of duties within the financial close and reporting process. For the remaining one material weakness, management has developed and continues to execute a remediation plan to address the previously disclosed material weakness around treatment of complex accounting transactions. We earned the AHRQ, the Agency for Healthcare Research and Quality certification as an accredited patient safety organization. We generated over $1.7 million in savings to patients through our dispensary co-pay assistance program. We added three new gain share contracts in Florida. We grew capitated membership by over 100,000 lives, and we completed six practice acquisitions. Now, I'll turn the call over to Mihir to provide additional detail on our Q4 and full year financial results. Thanks, Brad. Turning to Q4 2022 results. Consolidated revenue for Q4 2022 was $71 million, an increase of 36.6% compared to Q4 2021, and an increase of 9.9% compared to Q3 2022. Gross profit in Q4 2022 was $16 million, an increase of 87.6% compared to Q4 2021. Net loss for Q4 2022 was $9.5 million, a decrease of $1 million compared to Q4 2021. Adjusted EBITDA was $-4.9 million. Our adjusted EBITDA calculation includes provider start-up costs as well as consulting and legal fees associated with acquisitions. Further details on how we define adjusted EBITDA can be found in our 10-K. We have modified our adjusted EBITDA calculation to include board of directors' cash compensation. Talking about the full- year 2022. Consolidated revenue for the year- end December 31, 2022, was $252 million, an increase in 24.4% compared to prior year. Gross profit for the year ended December 31, 2022, was $52 million, an increase in 27.5% year-over-year. Net income for the year ended December 31, 2022, was $1.7 million, an increase of $12.6 million compared to the prior year. This was preliminarily due to increase in gross profit and the change in the fair value of warrants, earnout and conversion option derivative liabilities, offset by goodwill and intangible asset impairment charges and increased operating expenses. Adjusted EBITDA was $-24 million. SG&A expenses for the year ended December 31, 2022, were $119 million or 47.3% of revenue, compared with $83 million or 41.1% of revenue in prior year. During 2022, share-based compensation expense was $28 million. SG&A related to transaction cost was $3 million. The remainder of the SG&A growth was due to headcount and other costs associated with operating as a public company and to support our revenue growth and expansion into new markets. At year-end, our cash and cash equivalent balance was $14 million, and we had $118 million in investments. We expect this capital to be sufficient to support our operations and enhance our growth for 2023 and 2024. Turning to 2023 guidance. For the full- year 2023, we are guiding to a revenue range of $290 million-$320 million. This represents 15%-27% growth over 2022. Our gross profit guidance ranges from $60 million-$70 million, and our adjusted EBITDA guidance range from -$25 million to -$28 million. We expect to end the year with 1.75 million-2.4 million lives under capitation. I will now turn it back over to Brad for some summary remarks. Thank you, Mihir. 2022 was a pivotal year for TOI. During our first year as a publicly traded company, we invested to drive growth in our priority markets, expanded our gain share portfolio, and provided creative and innovative solutions to our partners. We expanded into our 15th market and surpassed 100 positions in APPs employed by the practice. We ended the year with a strong liquidity position and prioritized clinical outcomes by launching a patient safety organization. We expect 2023 to be another year of progress and growth. To ensure that success, our focus is aligned on thee primary areas. First, refining and optimizing our model in expansion markets, including optimizing referral capture and transitioning gain share contracts to population risk agreements. Second, growing our legacy markets by expanding service offerings in existing clinics and expanding to new counties. Finally, reducing cash burn by improving efficiency with new technology solutions, optimizing drug margins, and taking a more sustainable approach to new market entry. In summary, we are very optimistic about 2023 and look forward to sharing our progress as we move through the year. With that, I'll turn it back over to the operator to open it up for questions. Thank you. Thank you. We will now be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we pull for questions. Your first question comes from Brian Tanquilut with Jefferies. Please go ahead. Good afternoon, guys. How are you doing? Good. How are you doing? Good. I guess, Brad, my first question, since you alluded to the California issue, just wanted to hear if you can share any color with us on what's going on there and, you know, kind of like any cures or anything going on that will address that issue going forward? With respect to the California issue around the Medi-Cal drug prescribing, when California transitioned to a new vendor last year, first of last year, it essentially precluded us from prescribing drugs to a certain portion of our Medi-Cal patients because we operated as a medically integrated dispensary, not as a pharmacy. As we've discussed on previous calls, if and when we become licensed as a pharmacy, we would then be able to prescribe drugs to those patients. We have been endeavoring to become a pharmacy. It turns out, though, that our physician ownership in our practice is too high right now. We need to wait until our physician ownership in our practice goes below a certain threshold, and then we will apply to become a pharmacy and can reaccess those scripts. Until then, we can't access those bills. That's the latest on that issue. Gotcha. Understand. I guess, as I think about the guidance for EBITDA for this year, you know, relative to, Yeah, the budgets that you laid out during the De-SPAC. Just curious, you know, what has changed and what are the moving parts and how does that stack versus, you know, your expectations, say, maybe at the beginning of Q4 heading into this year? I think, you know, we have tried to put out guidance that we believe we can achieve. We're taking a conservative view to all four categories on guidance. There are certain realities that we haven't grown quite as fast as we projected to grow in some of our expansion markets. We haven't had the revenue growth needed to scale and cover some of those fixed SG&A expenses that we had expected, which is why you heard me talk about, you know, one of our priorities is optimizing our expansion markets. We have also seen a little bit of compression on IV drug margins as we started the year. That is to a large extent out of our control. We see a little bit of pressure on the buy and bill Part B IV margins, that is partially due to reimbursement changes and partially just due to drug mix, and things going on patent or off patent. We've taken a conservative view on guidance. Obviously, we hope to beat it. That's why you see, you know, slightly lower EBITDA than I think you know, we had originally predicted. Brad, maybe just to clarify or to, just check what's in the guide, any assumptions embedded for unannounced acquisitions in there right now? Mihir, you want to take that one? Sure. Hey, Brian. To your point, the guidance right now does not include any unannounced acquisitions that we might do in 2023. That would be upside from where we are right now. Got it. Okay, awesome. All right. Thank you, guys. Thank you, Brian. Next question, Sandy Draper with Guggenheim. Please go ahead. Thanks very much. I guess first just a follow-up to that. If you close the acquisitions from the Q4 that got pushed out, I guess that's the first question? Um, so we- Yeah, go ahead. Yeah. We have not closed any acquisitions, this, you know, in 2023 that we have not announced. Okay. The ones that were announced that you talked about in the Q3 and Q4 that got delayed that caused the lower revenue last year- Ahhh. Are those now closed? I see. No. Both of those we believe are unlikely to close ever. Oh, okay. Those are not in your guide. I was just trying to make sure if those were included? Yeah. It sounds like they're not, because it sounds like they're never happened. Yeah. We think for different reasons, both of those are likely not to happen. Never say never. They, you know, they can always come back. Our view right now is that they're probably not likely to happen. Okay. Got it. Maybe different. I appreciate the comments here around the EBITDA, and why it's a little lower. What's a little bit interesting to me is actually relative to my model, you finished stronger gross margin in 2022, and your guide is for a little bit of improvement in gross margin in 2023. I'm just trying to. It's not a lot, but, you know, midpoint, it's like 50 to 70 basis points. What are the drivers there? Just want to make sure those incremental costs you're talking about, are any of those in cost of goods, or are they all below cost of goods and down below in SG&A? Yeah, I can start. Mihir, you please fill in if I miss anything. The compression of IV drug margins on the buy-and-bill, that's in cost of goods sold, so that's reflected in our gross profit guidance. We have chosen several areas to invest in that hit our SG&A, including most importantly, our technology department and our clinical research department. We're investing in both of those departments, which is adding some to our SG&A. We're also we hope to get better scaling. Some of our SG&A is, you know, variable, and does scale up with the number of patients we treat. Obviously, we focus on trying to, you know, get that lower and lower every year as a percent of revenue. We think there are some opportunities to get better scaling out of our SG&A, but there's also some fixed SG&A with technology and clinical research that we've chosen to invest in for the future. Great. That's helpful. Thanks, Sandy. That sort of leads me into my final question. It may be still too early. I know you hired a new head of your clinical trials division or clinical research. Any updates? I guess it's been maybe 6 months or maybe it's only three. I can't remember. It may be too early, but any updates on sort of changes that are being made and how that's going? Thanks. Yeah, sure. We've been spending a lot of time focused on clinical research because we think it's a real differentiator of TOI's business model. Also, we think there's a lot of untapped potential, even though we, you know, we are very advanced, much further along than most community oncology practices. With respect to clinical research, we've seen examples of community practices out there that are further along than we are. So, we endeavor to be the best, and so we've set really high targets and goals for our clinical research department. A couple of the things that we have done, we rebranded the entire division. We used to call it ICRI, Innovative Clinical Research, and we rebranded that TOI Clinical Research, which we think is more understandable from a patient perspective. We've also changed a lot of our processes and protocols around patient identification so that we can start talking to patients earlier about clinical trials that they may be eligible for. We have very aggressive growth targets, we will see. We expect a lot of growth throughout 2023. We've started the year strong, that feels good. Those are some of the things that we're doing around TOI Clinical Research. Great. Thanks. Once again, if you would like to ask a question, please press star one on your telephone keypad. Your next question comes from Gary Taylor with Cowen and Company. Please go ahead. Hi, guys. A couple questions. One, just on the 2023 revenue guidance, how much of that pickup, year-over-year, you know, $40 million-$70 million pickup is already sort of, you know, in the bag, if you will, because of the acquisitions that, you know, have closed and you just get the pickup to the true or the annual run rate in 2023? Yeah, I mean, we, you know, we exited 2022 with, you know, if you look at our Q4 revenue, about $284 million run rate. You know, that's a significant portion of the way there already, just with our exit run rate. Q4 seems to be a little bit stronger. There's a bit of seasonality, so it's not a perfect annualization. Right. That gives you a sense. Okay. I didn't know if all the deals were in there for the full Q4 or not. That's helpful. On your new gain share contracts, the three in Florida, was one of those with ChenMed or all those were with ChenMed or what's or different payers or providers? Just one of those was with ChenMed, yeah. Is that, you know, like, single county, kind of a pilot? I mean, obviously there are, you know, multiple counties, multiple states. What's the outlook that that relationship could get larger? Yeah. I mean, we have a lot of optimism for that relationship. We've started partnering with them in Central Florida. And, you know, we hope to expand that to many other locations. The initial focus is Central Florida, and then we'll follow that on with other places, for example, South Florida, and elsewhere where we have market overlap with ChenMed. The $59 million of non-current investments, I presume just because you've got plenty of liquidity and maybe more than you'll put to use right away, made more sense to do something that would earn a little more. Can you tell us what that's in? Why don't you take that, Mihir? Trade. Yes, I can take that. It's mostly in the T-bills, but the way that the GAAP accounting allows us to recognize it needs to be in non-current, but most of it is available for our operations and acquisition use. Okay. Thank you. Thank you. Thank you. I would like to turn the floor over to Brad Hively for closing remarks. Okay. Well, thank you everybody for joining our call today. We look forward to following up with you in the coming weeks. We're very excited about TOI's path ahead, and we look forward to updating you on our progress on the next earnings call. Thank you and have a good evening. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.